




**Figure 1: Chemical Structures of Illustrative Nucleosides**




$\beta$ -D-2'-CH<sub>3</sub>-riboG




$\beta$ -D-2'-CH<sub>3</sub>-riboC




$\beta$ -D-2'-CH<sub>3</sub>-riboU




$\beta$ -D-2'-CH<sub>3</sub>-riboA




$\beta$ -D-2'-CH<sub>3</sub>-riboI




$\beta$ -D-2'-CH<sub>3</sub>-riboT




$\beta$ -D-1'-CH<sub>3</sub>-riboA



$\beta$ -D-1'-CH<sub>3</sub>-riboG



FIAU



Ribavirin

Figure 2: Screening Pharmacokinetics of  $\beta$ -D-2'-CH<sub>3</sub>-riboG in Cynomolgus Monkeys




Figure 3 Pharmacokinetics of  $\beta$ -D-2'-CH<sub>3</sub>-riboG in Cynomolgus Monkeys







Figure 4: BVDV Cell Protection Assay (CPA) Of  $\beta$ -D-2'-CH<sub>3</sub>-riboG



### Cell Protection Assay






Figure 5: BVDV Cell Protection Assay (CPA) of Ribavirin



### Cell Protection Assay




Figure 6: BVDV Cell Protection Assays




Figure 7: Plaque Purified BVDV




Figure 8: BVDV Plaque Assay of β-D-2'-CH<sub>3</sub>-riboU





Figure 9: Yield Reduction Assay of  $\beta$ -D-2'-CH<sub>3</sub>-riboG



4-log virus reduction at 9  $\mu$ M

Figure 10: BVDV Yield Reduction Assay for  $\beta$ -D-2'-CH<sub>3</sub>-riboC

0  $\mu$ M




No  
Virus

0.5  $\mu$ M




2.7  $\mu$ M

0.8  $\mu$ M



4  $\mu$ M

1.2  $\mu$ M



6  $\mu$ M

1.5  $\mu$ M



9  $\mu$ M